AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...

Jan. 29, 2025 /PRNewswire/ -- In response to growing demand for personalized, patient-centric aesthetic solutions 1,2, Allergan Aesthetics, an AbbVie Company, is proud to unveil the new AA ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

NORTH CHICAGO, Ill., Jan. 24, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, continues to innovate and elevate the patient journey with ...

New AA (Allergan Aesthetics) Signature Program provides a personalized ... generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and ...

Jan. 24, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, continues to innovate and elevate the patient journey with the launch of its new ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on AbbVie (ABBV – Research Report), with a price target ...